These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27191770)

  • 21. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.
    Yee KL; McCrea J; Panebianco D; Liu W; Lewis N; Cabalu T; Ramael S; Wrishko RE
    Clin Drug Investig; 2018 Jul; 38(7):631-638. PubMed ID: 29705869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
    Cui D; Cabalu T; Yee KL; Small J; Li X; Liu B; Maciolek C; Smith S; Liu W; McCrea JB; Prueksaritanont T
    Xenobiotica; 2016 Oct; 46(10):882-95. PubMed ID: 26864332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 25. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.
    Masuyama T; Sanui M; Yoshida N; Iizuka Y; Ogi K; Yagihashi S; Nagatomo K; Sasabuchi Y; Lefor AK
    Psychogeriatrics; 2018 May; 18(3):209-215. PubMed ID: 29423967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
    Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
    Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
    Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan.
    Takeuchi Y; Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y
    Curr Med Res Opin; 2020 Mar; 36(3):465-471. PubMed ID: 31793350
    [No Abstract]   [Full Text] [Related]  

  • 29. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
    Petrous J; Furmaga K
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Herring WJ; Ceesay P; Snyder E; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D
    Alzheimers Dement; 2020 Mar; 16(3):541-551. PubMed ID: 31944580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suvorexant: something new for sleep?
    Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
    Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suvorexant for the prevention of delirium: A meta-analysis.
    Xu S; Cui Y; Shen J; Wang P
    Medicine (Baltimore); 2020 Jul; 99(30):e21043. PubMed ID: 32791676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of suvorexant in the management of insomnia.
    Sutton EL
    Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial.
    Hatta K; Kishi Y; Wada K; Takeuchi T; Ito S; Kurata A; Murakami K; Sugita M; Usui C; Nakamura H;
    J Clin Psychiatry; 2017; 78(8):e970-e979. PubMed ID: 28767209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder.
    Iwata M; Kaneko K
    Neuropsychopharmacol Rep; 2020 Dec; 40(4):383-387. PubMed ID: 32990413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suvorexant for the treatment of insomnia.
    Jacobson LH; Callander GE; Hoyer D
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.